10-Q: ChromaDex Reports Q3 2024 Results, Secures Settlement Agreement with Dartmouth College

ChromaDex Corporation announced its Q3 2024 financial results, highlighted by a settlement agreement with Dartmouth College waiving $3.5 million in fees, and a 31% increase in net sales compared to Q3 2023.

Summary

• ChromaDex Corporation reported a net income of $1.878 million for the third quarter of 2024, a significant improvement compared to a net loss of $0.959 million in the same period last year.
• Net sales for the quarter reached $25.580 million, a 31% increase from $19.495 million in Q3 2023, driven by growth in both consumer products and ingredient sales.
• The company's gross profit for the quarter was $16.240 million, up from $11.969 million in the prior year.
• Operating expenses totaled $14.638 million, compared to $13.116 million in Q3 2023.
• For the nine months ended September 30, 2024, ChromaDex reported a net income of $1.371 million, a turnaround from a net loss of $5.052 million in the same period of 2023.
• Year-to-date net sales reached $70.472 million, a 13% increase from $62.374 million in the prior year.
• A settlement agreement with Dartmouth College was reached, waiving approximately $3.5 million in royalty and license maintenance fees.
• This waiver is contingent upon the company securing a court surety bond within 30 days following the final judgment in the Delaware patent infringement case against Elysium.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong sales growth and a return to profitability. The settlement with Dartmouth College is a significant positive development. However, the ongoing litigation with Elysium and the need for potential future capital raises introduce some uncertainty.

Positives

• The company achieved profitability in both Q3 2024 and for the nine months ended September 30, 2024, a significant turnaround from previous losses.
• Strong sales growth was seen across both consumer products and ingredient segments.
• The settlement with Dartmouth College eliminates a significant financial liability.
• The company's cash position remains strong with $32.2 million in unrestricted cash and cash equivalents.
• Gross profit margins improved slightly compared to the same periods in 2023.

Negatives

• Operating expenses increased to $14.638 million in Q3 2024, compared to $13.116 million in Q3 2023.
• The settlement with Dartmouth College is contingent on securing a court surety bond related to the Elysium litigation.
• The company has a history of operating losses and may need additional financing in the future.
• The company relies on a single supplier for NR, which could pose a risk to the supply chain.

Risks

• The company's reliance on a single supplier for NR could lead to supply chain disruptions.
• The settlement with Dartmouth College is contingent on securing a court surety bond, which may present a challenge.
• The company may need to seek additional capital in the next twelve months to fund its operations and strategic objectives.
• The company is involved in ongoing litigation with Elysium, which could have a material adverse effect on its business and financial results.
• The company's operating results may fluctuate significantly, making future results difficult to predict.
• The company is subject to various regulations and compliance requirements, which could lead to fines, penalties, and additional costs.

Future Outlook

The company anticipates that its current unrestricted cash and cash equivalents and cash to be generated from net sales will be sufficient to meet its financial obligations as they become due over at least the next twelve months. The company may seek additional capital within the next twelve months to fund its projected operating plans and longer-term strategic objectives. The company expects to increase its investment in R&D projects, including clinical trials, throughout 2024 compared to 2023. On a full year basis for 2024, the company expects its sales and marketing spend to increase with similar efficiencies compared to 2023.

Management Comments

• Management assessed that there were conditions and events, including a history of recurring operating losses and a history of negative cash flows from operating activities, that raised substantial doubt about the Company's ability to meet its obligations as they became due over the next twelve months from the date of issuance of the Companys third quarter of 2024 interim Unaudited Condensed Consolidated Financial Statements.
• Management evaluated these conditions and anticipates that its current unrestricted cash and cash equivalents and cash to be generated from net sales will be sufficient to meet its financial obligations as they become due over at least the next twelve months from the issuance date of these Unaudited Condensed Consolidated Financial Statements.
• The Company may, however, seek additional capital within the next twelve months, both to fund its projected operating plans after the next twelve months and/or to fund the Companys longer-term strategic objectives.

Industry Context

The report reflects ChromaDex's position in the growing market for healthy aging products, particularly those related to NAD+ precursors. The company's focus on scientific research and partnerships with leading institutions positions it as a key player in this emerging field. The settlement with Dartmouth College also highlights the importance of intellectual property in this sector.

Comparison to Industry Standards

• ChromaDex's 31% increase in net sales for Q3 2024 is a strong performance compared to the broader dietary supplement industry, which has seen more moderate growth.
• The company's shift to profitability is notable, as many companies in the early stages of the nutraceutical market struggle to achieve consistent profitability.
• Compared to competitors like Elysium, with whom ChromaDex has ongoing litigation, ChromaDex's financial performance appears more stable and positive in the current quarter.
• The company's focus on scientific research and clinical trials is a differentiator compared to other companies in the dietary supplement space, which often lack robust scientific backing.
• The settlement with Dartmouth College is a positive development, as it removes a significant financial liability and strengthens the company's intellectual property position, which is crucial in the competitive nutraceutical market.

Management Changes

Legal Proceedings

• The company is involved in ongoing litigation with Elysium Health, Inc. and Elysium Health LLC, including multiple complaints and counterclaims in California and New York, as well as a patent infringement complaint in Delaware.
• The company reached a settlement agreement with Elysium in the Southern District of New York action, which was enforced by the court.
• The company is appealing the court's decision in the Delaware patent infringement case, which found the claims of the 807 and 086 patents invalid.
• The company is also involved in a dispute with a licensor regarding sublicense fees.

Related Party Transactions

• Prior to August 20, 2024, A.S. Watson Group was considered a related party through common ownership. Sales to A.S. Watson Group were $2.0 million in Q3 2024 and $8.7 million for the nine months ended September 30, 2024.
• As of September 30, 2024, trade receivables from A.S. Watson Group were $2.0 million.

Stakeholder Impact

• Shareholders will benefit from the company's return to profitability and strong sales growth.
• Employees may benefit from the company's improved financial position and potential for future growth.
• Customers will benefit from the company's continued focus on product quality and innovation.
• Suppliers may benefit from the company's increased sales and production volumes.
• Creditors may benefit from the company's improved financial stability and ability to meet its obligations.

Next Steps

• The company will need to secure a court surety bond within 30 days following the final judgment in the Delaware patent infringement case against Elysium to finalize the settlement agreement with Dartmouth College.
• The company will continue to negotiate a new supply agreement with W.R. Grace & Co.-Conn.
• The company will continue to pursue new partnerships and business opportunities to diversify its customer base.
• The company will continue to monitor the creditworthiness and payment behavior of its major customers.
• The company will continue to invest in R&D projects, including clinical trials.

Key Dates

Keywords

ChromaDex, Niagen, nicotinamide riboside, NAD+, dietary supplements, ingredients, settlement agreement, Dartmouth College, Elysium, financial results, Q3 2024, patent infringement, litigation